Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders for Pliant Therapeutics, Inc., held on June 11, 2026. As of the record date of April 15, 2026, there were 61,914,664 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on three proposals. The final certified results are as follows:
- Proposal No. 1 (Election of Class III Directors): Approved.
- Bernard Coulie, M.D., Ph.D., MBA: 18,824,540 For; 11,807,308 Withhold.
- Gayle Crowell: 18,186,914 For; 12,444,934 Withhold.
- Steve Krognes, MBA: 19,299,728 For; 11,332,120 Withhold.
- Total Broker Non-Votes: 11,895,135 shares.
- Proposal No. 2 (Executive Compensation Advisory Vote): Approved.
- For: 15,282,788; Against: 14,572,455; Abstain: 776,605.
- Total Broker Non-Votes: 11,895,135 shares.
- Proposal No. 3 (Ratification of Auditors): Approved.
- For: 41,710,604; Against: 747,140; Abstain: 69,239.
- Total Broker Non-Votes: None.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the results of the shareholder vote.
Key Facts for Investor Verification
- Three new Class III directors were elected to serve until the 2029 Annual Meeting.
- The executive compensation advisory vote passed with a narrow margin (For: 15.3M vs. Against: 14.6M).
- Deloitte & Touche LLP was ratified as the independent auditor for the fiscal year ending December 31, 2026.
- Significant broker non-votes (approx. 11.9M shares) occurred for the director election and compensation proposals but did not affect the ratification of the auditor.